Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1981 Nov;74(3):611–617. doi: 10.1111/j.1476-5381.1981.tb10471.x

Effects of a salt of cholestyramine and 2-[4-(p-chlorobenzoyl)phenoxy]2-methyl propionic acid (alpha-1081) on biliary lipid secretion in rats.

R Aldini, L Barbara, A Benelli, V Borzatta, S Geminiani, G Mascellani, A Morselli, A Roda, E Roda
PMCID: PMC2071745  PMID: 6895340

Abstract

1 Hypolipidaemic agents may increase biliary cholesterol in man, inducing a supersaturated bile. 2 To evaluate this possible side-effect, we have studied bile lipid secretion over a period of 8 h with intact enterohepatic circulation and 4 h with complete interruption in rats treated for two months with a salt of cholestyramine and 2-[4-(p-chlorobenzoyl)-phenoxy]2-methyl propionic acid (alpha-1081, 1.150 g/kg body wt., daily), cholestyramine (1.125 g/kg body wt. daily), procetofenic acid (25 mg/kg body wt. daily) and saline respectively (six rats for each group). 3 Cholesterol saturation index significantly (P less than 0.005) increased (from 0.21 +/- 0.01 to 0.39 +/- 0.09, mean +/- s.d.), in rats fed with procetofenic acid but it did not in alpha-1081- and cholestyramine-treated animals. 4 Procetofenic acid and, to a lesser extent, cholestyramine increased the bile flow. Procetofenic acid increased cholesterol secretion from 0.45 +/- 0.17 to 0.94 +/- 0.19 mumol kg-1 body wt. h-1 (mean +/- s.d.). 5 Cholestyramine increased both serum cholesterol and bile acid secretion from 0.45 +/- 0.17 to 0.68 +/- 0.10 and 25.8 +/- 9.48 to 39.96 +/- 6.68 mumol kg-1 body wt. h-1 respectively; alpha-1081, on the contrary, had no effect on bile lipid secretion. 6 These data suggest that alpha-1081 may be used as a new hypolipidaemic drug without any risk of increasing cholesterol in bile.

Full text

PDF
611

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Admirand W. H., Small D. M. The physicochemical basis of cholesterol gallstone formation in man. J Clin Invest. 1968 May;47(5):1043–1052. doi: 10.1172/JCI105794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Angelin B., Einarsson K., Leijd B. Biliary lipid composition during treatment with different hypolipidaemic drugs. Eur J Clin Invest. 1979 Jun;9(3):185–190. doi: 10.1111/j.1365-2362.1979.tb00921.x. [DOI] [PubMed] [Google Scholar]
  3. Angelin B., Einarsson K., Leijd B. Effect of chenodeoxycholic acid on serum and biliary lipids in patients with hyperlipoproteinaemia. Clin Sci Mol Med. 1978 Apr;54(4):451–455. doi: 10.1042/cs0540451. [DOI] [PubMed] [Google Scholar]
  4. Cohen B. I., Raicht R. F., Shefer S., Mosbach E. H. Effects of clofibrate on sterol metabolism in the rat. Biochim Biophys Acta. 1974 Oct 16;369(1):79–85. doi: 10.1016/0005-2760(74)90194-5. [DOI] [PubMed] [Google Scholar]
  5. Cooper J., Geizerova H., Oliver M. F. Letter: Clofibrate and gallstones. Lancet. 1975 May 10;1(7915):1083–1083. doi: 10.1016/s0140-6736(75)91845-0. [DOI] [PubMed] [Google Scholar]
  6. Dowling R. H., Mack E., Small D. M. Biliary lipid secretion and bile composition after acute and chronic interruption of the enterohepatic circulation in the Rhesus monkey. IV. Primate biliary physiology. J Clin Invest. 1971 Sep;50(9):1917–1926. doi: 10.1172/JCI106684. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fausa O., Skålhegg B. A. Quantitative determination of bile acids and their conjugates using thin-layer chromatography and a purified 3alpha-hydroxysteroid dehydrogenase. Scand J Gastroenterol. 1974;9(3):249–254. [PubMed] [Google Scholar]
  8. Grundy S. M., Mok H. Y. Colestipol, clofibrate, and phytosterols in combined therapy of hyperlipidemia. J Lab Clin Med. 1977 Feb;89(2):354–366. [PubMed] [Google Scholar]
  9. Harvengt C., Heller F., Desager J. P. Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias. Artery. 1980;7(1):73–82. [PubMed] [Google Scholar]
  10. Hegardt F. G., Dam H. The solubility of cholesterol in aqueous solutions of bile salts and lecithin. Z Ernahrungswiss. 1971 Apr;10(3):223–233. doi: 10.1007/BF02020933. [DOI] [PubMed] [Google Scholar]
  11. Hofmann A. F., Small D. M. Detergent properties of bile salts: correlation with physiological function. Annu Rev Med. 1967;18:333–376. doi: 10.1146/annurev.me.18.020167.002001. [DOI] [PubMed] [Google Scholar]
  12. Roda A., Festi D., Sama C., Mazzella G., Alini R., Roda E., Barbara L. Enzymatic determination of cholesterol in bile. Clin Chim Acta. 1975 Nov 3;64(3):337–341. doi: 10.1016/0009-8981(75)90364-2. [DOI] [PubMed] [Google Scholar]
  13. Rozé C., Cuchet P., Souchard M., Vaille C., Debray C. The effects of tiadenol, clofibrate and clofibride on bile composition in the rat. Eur J Pharmacol. 1977 May 1;43(1):57–64. doi: 10.1016/0014-2999(77)90160-1. [DOI] [PubMed] [Google Scholar]
  14. Sturdevant R. A., Pearce M. L., Dayton S. Increased prevalence of cholelithiasis in men ingesting a serum-cholesterol-lowering diet. N Engl J Med. 1973 Jan 4;288(1):24–27. doi: 10.1056/NEJM197301042880106. [DOI] [PubMed] [Google Scholar]
  15. Takayama M., Itoh S., Nagasaki T., Tanimizu I. A new enzymatic method for determination of serum choline-containing phospholipids. Clin Chim Acta. 1977 Aug 15;79(1):93–98. doi: 10.1016/0009-8981(77)90465-x. [DOI] [PubMed] [Google Scholar]
  16. Thomas P. J., Hofmann A. F. Letter: A simple calculation of the lithogenic index of bile: expressing biliary lipid composition on rectangular coordinates. Gastroenterology. 1973 Oct;65(4):698–700. [PubMed] [Google Scholar]
  17. van der Linden W., Nakayama F. Change of bile composition in man after administration of cholestyramine (a gallstone dissolving agent in hamsters). Acta Chir Scand. 1969;135(5):433–438. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES